{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:21:36Z","timestamp":1791490896218,"version":"4.3.4"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":197,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Depression and Anxiety"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. The efficacy and safety of esketamine nasal spray (ESK) were established in registration trials in patients with treatment\u2010resistant depression (TRD). This French real\u2010world study aimed to describe the treatment patterns, effectiveness, and safety of ESK in TRD patients over a 12\u2010month follow\u2010up. <jats:italic>Materials and Methods<\/jats:italic>. This study used secondary data from patient files of hospital\u2010based psychiatrists and started during the first French patient early access to ESK. The response and remission rates with ESK were analyzed using the total score of the Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS). The time to first treatment response and work resumption were described (Kaplan\u2013Meier method). Adverse events (AEs) were analyzed. <jats:italic>Results<\/jats:italic>. Prior to ESK initiation, the 157 analyzed patients (age\u2009\u2264\u200965 years, 82.8%; female, 66.2%) had depression for 10.5 years (median, IQR, 4.2\u201321.2) and received a median of 6 (3\u20138) previous treatment lines. At ESK initiation, the mean\u2009\u00b1\u2009SD total MADRS score was 32.1\u2009\u00b1\u20097.7. At that time, ESK was combined with antidepressants (93.6% of patients; SNRI, 65.0%; SSRI, 57.3%) and\/or other potentiation strategy (63.1%; atypical antipsychotics, 36.3%; lithium, 25.6%; antiepileptics, 21.7%). During the 12\u2010month follow\u2010up, 125 patients (79.6%) discontinued ESK. The median duration of ESK treatment was 19.4 weeks (IQR, 4.4\u201340.1). At 1 month after ESK initiation, 40.2% of still treated patients met criteria for clinical response and 19.7% for remission (median time to response, 5.7 weeks; 95% CI (4.1\u20138.4)). 82.6% of active patients were on sick leave at ESK initiation; the work resumption rate was 24% (13%\u201340%) 12 weeks later. AEs were reported in 68.6% of patients, serious AEs in 17.2%, and AEs leading to ESK discontinuation in 14.6%. <jats:italic>Conclusion<\/jats:italic>. These real\u2010world effectiveness and safety data were consistent with findings from previous clinical trials, describing the real\u2010life clinical experience of patients receiving ESK and confirming that ESK has its place in therapy for the treatment of TRD.<\/jats:p>","DOI":"10.1155\/2024\/7262794","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T09:38:27Z","timestamp":1721122707000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Use of Esketamine Nasal Spray in Patients with Treatment\u2010Resistant Depression in Routine Practice: A Real\u2010World French Study"],"prefix":"10.1155","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-4019","authenticated-orcid":false,"given":"Ludovic","family":"Samalin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9016-955X","authenticated-orcid":false,"given":"Lila","family":"Mekaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-0403","authenticated-orcid":false,"given":"Maud","family":"Roth\u00e4rmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-8535","authenticated-orcid":false,"given":"Anne","family":"Sauvaget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5889-8138","authenticated-orcid":false,"given":"Clotilde","family":"Wicart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3955-2726","authenticated-orcid":false,"given":"Julien","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1985-4149","authenticated-orcid":false,"given":"Vanessa","family":"Cohignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2710-5447","authenticated-orcid":false,"given":"Emeline","family":"Gaudre-Wattinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"e_1_2_9_1_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030480"},{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S198774"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2237-x"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120"},{"key":"e_1_2_9_5_2","unstructured":"FondaMental Foundation Resistant depression 2023 Accessed 18 Aprilhttps:\/\/www.fondation-fondamental.org\/les-maladies-mentales\/depression-resistante\/la-maladie."},{"key":"e_1_2_9_6_2","first-page":"28","article-title":"Prevalence of depressive episodes in France among 18\u201385 year-olds. Results from the 2021 Heath Barometer survey","volume":"2","author":"Leon C.","year":"2023","journal-title":"BEH"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.12.090"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275299"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.11.004"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0149"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.09.005"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01577-5"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304145"},{"key":"e_1_2_9_19_2","unstructured":"Food and Drug Administration FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic 2023 Accessed 27 Novemberhttps:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified."},{"key":"e_1_2_9_20_2","unstructured":"European Medicines Agency Spravato 28 mg nasal spray solution. Summary of Product Characteristics 2024 Accessed 02 Februaryhttps:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spravato-epar-product-information_en.pdf."},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.043"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2023.06.016"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2208993"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13296"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2023.02.010"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2023.04.011"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1394787"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2022.2030757"},{"key":"e_1_2_9_29_2","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 Transparency committee opinion. 24 June 2020. Esketamine SPRAVATO 28 mg nasal spray solution 2023 Accessed 18 Aprilhttps:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-09\/spravatoo_summary_ct18432_epi673.pdf."},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20050"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.09.030"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2023.09.003"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115378"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.01.002"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2023.11.029"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1017\/S204579602100072X"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10120962"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2021.03.002"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2023.09.007"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2024\/7262794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T09:38:33Z","timestamp":1721122713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2024\/7262794"}},"subtitle":[],"editor":[{"given":"Subho","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1155\/2024\/7262794"],"URL":"https:\/\/doi.org\/10.1155\/2024\/7262794","archive":["Portico"],"relation":{},"ISSN":["1091-4269","1520-6394"],"issn-type":[{"value":"1091-4269","type":"print"},{"value":"1520-6394","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"7262794"}}